Attributes
Improved Medical Attributes
Medical benefits of our ProLipTagTM based prodrugs:
Improved efficacy and safety profile
Preclinical studies and in-vitro experiments on a number of drugs have shown specific improvements in biological activity compared with the parent drug. Chimerix has identified candidate drugs showing improved efficacy and improved safety profiles, thus an improved therapeutic index.
Convenient oral administration
Chimerix applied the our ProLipTagTM technology on very active antiviral drugs with toxicity and mode of administration limitations. Chimerix has generated promising data showing that drugs that currently are limited to administration by injection only can be readily absorbed orally or transdermally by topical applications. These enhancements provide improved ease of administration and greater patient compliance.
Prolonged effect allows more convenient dosing schedule
An important characteristic of a therapeutic drug is the time-span for which it is active. The period during which a therapeutic concentration of drug is sustained in a given cell will influence the effectiveness of the treatment. Chimerix initial human data with CMX001 show much higher bioavailability than the parent drug. This will allow less frequent dosing and hence a more convenient and patient friendly treatment.
Business benefits
Business benefits of our ProLipTagTM based prodrugs:
Strong patent protection as a New Chemical Entity
Chimerix prodrugs are protected as New Chemical Entities with strong composition of matter patents.
Product life cycle management
Our prodrugs are a very effective product life cycle renewal tool based on improved drug properties for patients.
Reduced risk and development cost
ProLipTagTM based prodrugs of existing drugs will have a high probability of success as the safety and efficacy of the parent drug have already been proven. The past experience of a certain drug can be used to optimize the preclinical and clinical studies that need to be performed to get the new product to market. A drug development project for a ProLipTagTM based prodrugs will be shorter and less costly compared with drug with unproven new mechanisms of action, maximizing the return of investment spent to bringing the drug to the market.
Opportunity to expand use in new therapeutic indications
Improved efficacy and lower toxicity potentially expand the use of our ProLipTagTM based prodrugs into new therapeutic indications.